Novo Nordisk Yönetim

Yönetim kriter kontrolleri 3/4

Novo Nordisk CEO'su Lars Jorgensen, Jan2017 tarihinde atandı, in görev süresi 7.83 yıldır. şirketin hisselerinin 0.002% doğrudan sahiptir ve bu hisselerin değeri MX$ 189.47M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.8 yıl ve 6.7 yıldır.

Anahtar bilgiler

Lars Jorgensen

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	7.8yrs
CEO sahipliği	0.002%
Yönetim ortalama görev süresi	3.8yrs
Yönetim Kurulu ortalama görev süresi	6.7yrs

Son yönetim güncellemeleri

Güncelleme yok

Recent updates

CEO Tazminat Analizi

Lars Jorgensen'un ücretlendirmesi Novo Nordisk'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	DKK 95b
Jun 30 2024	n/a	n/a	DKK 90b
Mar 31 2024	n/a	n/a	DKK 89b
Dec 31 2023	n/a	n/a	DKK 84b
Sep 30 2023	n/a	n/a	DKK 75b
Jun 30 2023	n/a	n/a	DKK 67b
Mar 31 2023	n/a	n/a	DKK 61b
Dec 31 2022	DKK 60m	DKK 17m	DKK 56b
Sep 30 2022	n/a	n/a	DKK 53b
Jun 30 2022	n/a	n/a	DKK 51b
Mar 31 2022	n/a	n/a	DKK 49b
Dec 31 2021	DKK 58m	DKK 17m	DKK 48b
Sep 30 2021	n/a	n/a	DKK 46b
Jun 30 2021	n/a	n/a	DKK 44b
Mar 31 2021	n/a	n/a	DKK 43b
Dec 31 2020	DKK 57m	DKK 14m	DKK 42b
Sep 30 2020	n/a	n/a	DKK 42b
Jun 30 2020	n/a	n/a	DKK 41b
Mar 31 2020	n/a	n/a	DKK 40b
Dec 31 2019	DKK 55m	DKK 14m	DKK 39b
Sep 30 2019	n/a	n/a	DKK 39b
Jun 30 2019	n/a	n/a	DKK 38b
Mar 31 2019	n/a	n/a	DKK 38b
Dec 31 2018	DKK 41m	DKK 11m	DKK 39b
Sep 30 2018	n/a	n/a	DKK 38b
Jun 30 2018	n/a	n/a	DKK 39b
Mar 31 2018	n/a	n/a	DKK 39b
Dec 31 2017	DKK 32m	DKK 9m	DKK 38b

Tazminat ve Piyasa: Lars şirketinin toplam tazminatının MX pazarındaki benzer büyüklükteki şirketlerle karşılaştırıldığında makul olup olmadığını tespit etmek için yeterli veri yok.

Tazminat ve Kazançlar: Lars 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Lars Jorgensen (58 yo)

7.8yrs

Görev süresi

DKK 60,100,000

Tazminat

Mr. Lars Fruergaard Jorgensen serves as Director at Danmarks Nationalbank since April 2024. He has been Chief Executive Officer and President of Novo Nordisk A/S since January 2017and serves as its Member...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Lars Jorgensen	President	7.8yrs	DKK 60.10m	0.0021% MX$ 189.5m
Karsten Knudsen	Executive VP	6.8yrs	DKK 21.50m	0.000010% MX$ 906.6k
Henrik Wulff	Executive VP of Product Supply	no data	DKK 22.00m	0.000060% MX$ 5.4m
Camilla Sylvest	Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board	no data	DKK 21.30m	Veri yok
Martin Lange	Executive VP of Development & Member of the Management Board	3.8yrs	DKK 20.90m	Veri yok
Marcus Schindler	EVP of Research & Early Development	3.7yrs	DKK 20.90m	Veri yok
Maziar Doustdar	Executive VP of International Operations & Member of the Management Board	no data	Veri yok	0.0011% MX$ 102.4m
Douglas Langa	Executive VP of North America Operations & Member of Management Board	no data	Veri yok	Veri yok
Ludovic Helfgott	Executive VP	no data	Veri yok	Veri yok
Tania Sabroe	Executive VP of Global People & Organisation and Member of Management Board	1.7yrs	Veri yok	Veri yok
David Moore	Executive VP of Corporate Development & Member of Management Board	1.7yrs	Veri yok	Veri yok
Jacob Martin Rode	Head of Investor Relations	no data	Veri yok	Veri yok

3.8yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: NVO N 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Sylvie Gregoire	Independent Director	9.7yrs	DKK 1.80m	Veri yok
Helge Lund	Independent Chairman of the Board	7.7yrs	DKK 3.10m	Veri yok
Henrik Poulsen	Vice Chairman of the Board	3.7yrs	DKK 2.00m	Veri yok
Laurence Debroux	Independent Director	5.7yrs	DKK 2.00m	Veri yok
Martin MacKay	Independent Director	6.7yrs	DKK 1.70m	Veri yok
Andreas Fibig	Independent Director	6.7yrs	DKK 1.40m	Veri yok
Kasim Kutay	Non-Independent Director	7.7yrs	DKK 1.20m	Veri yok
Christina Law	Independent Director	2.7yrs	DKK 1.30m	Veri yok
Liselotte Hyveled	Employee Representative Director	2.7yrs	DKK 800.00k	0% MX$ 0
Mette Jensen	Employee Non-Independent Representative Director	6.7yrs	DKK 1.20m	Veri yok
Thomas Rantzau	Employee Representative Non-Independent Director	6.8yrs	DKK 1.00m	Veri yok
Elisabeth Christensen	Employee Representative Director	2.7yrs	DKK 800.00k	Veri yok

6.7yrs

Ortalama Görev Süresi

58.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: NVO N 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.7 yıldır).

Novo Nordisk Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Recent updates

Novo Nordisk A/S to Report Q2, 2025 Results on Aug 06, 2025

Novo Nordisk A/S Provides Earnings Guidance for 2024

Novo Nordisk A/S Announces Results from Part 1 of the Ongoing ESSence Trial

Novo Nordisk A/S Announces Monlunabant Phase 2A Trial in Obesity Successfully Completed

Aragen Life Sciences Reportedly Plans to Dilute About 10% Stake

Novo Nordisk A/S Decides to Pay Interim Dividend for 2024, Payable on 19 August 2024 for A and B Shares and 26 August 2024 for ADRs

European Regulatory Authority Adopts A Positive Opinion for an Update of the Wegovy® Label to Reflect Risk Reduction of Major Adverse Cardiovascular Events

Novo Nordisk Receives Complete Response Letter in the US for Once-Weekly Basal Insulin Icodec

Novo Nordisk Announces Wegovy (Semaglutide Injection) Available in Canada

Mankind Reportedly Joins Race for Healthium Medtech

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Cardior Pharmaceuticals GmbH from EQT Life Sciences and others for €1.03 billion.

Novo Nordisk Announces Awiqli Recommends for Approval for the Treatment of Diabetes by the European Regulatory Authorities

Novo Nordisk Announces US Food and Drug Administration Approves Wegovy® Based on A Supplemental New Drug Application for the Indication of Reducing Risk of Major Dose Cardiovascular Events

Novo Nordisk A/S Proposes Final Dividend for the Year 2023

Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 20,000 million worth of its shares.

Novo Nordisk A/S Announces Topline Results from the Combine 3 Phase 3A Trial of Once-Weekly IcoSema

Novo Nordisk A/S to Report First Half, 2024 Results on Aug 07, 2024

Novo Nordisk Revises Earnings Guidance for the Year 2023

Novo Nordisk to Stop the Once-Weekly Injectable Semaglutide Kidney Outcomes Trial, Flow, Based on Interim Analysis

Novo Nordisk A/S (CPSE:NOVO B) acquired Embark Biotech ApS for approximately €470 million.

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Inversago Pharma Inc. from Genesys Capital Partners Inc., Accel-Rx, Tarnagulla Ventures Pty. Ltd., Fonds de solidarité FTQ, adMare BioInnovations and others for $1 billion.

Novo Nordisk A/S Provides Earnings Guidance for the Year 2023

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire a 64.4% stake in Biocorp Production (ENXTPA:ALCOR) for €99.1 million.

Novo Nordisk Enters into Exclusive Negotiations to Acquire A Controlling Stake in Bicorp, to Be Followed by A Tender Offer on All Remaining Shares

Novo Nordisk A/S Announces Headline Results from OASIS 1

Novo Nordisk A/S to Report Fiscal Year 2023 Results on Jan 31, 2024

Heartseed and Novo Nordisk A/S Announces First Patient Dosed in Clinical Study with HS-001 – A Cell Therapy Designed to Restore Heart Function in People with Advanced Heart Failure

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş